Two United State pharmaceutical companies have asked the Supreme Court to reinstate mail-order access to the abortion pill mifepristone, following a recent appeals court decision that temporarily halted its distribution by mail across the country.
Danco Laboratories and GenBioPro submitted emergency applications after a federal appeals court ruling restricted delivery of the drug, a move that could significantly limit access, particularly in states where abortion is banned or heavily restricted.
The decision marks a major development in ongoing legal disputes surrounding mifepristone, which was first approved by the U.S. Food and Drug Administration in 2000.
The drug is used in combination with misoprostol and accounts for roughly two-thirds of abortions in the United States.
The legal battle is part of a broader conflict over abortion access that has intensified since the Supreme Court’s 2022 ruling in Dobbs v. Jackson Women’s Health Organization, which overturned the constitutional right to abortion established under Roe v. Wade.
Since then, many states have imposed strict abortion limits, increasing reliance on medication-based procedures.
The recent appeals court decision came from the U.S. Court of Appeals for the Fifth Circuit, which indicated that a lawsuit filed by the state of Louisiana challenging federal regulations on mifepristone could succeed.
Louisiana officials argue that regulators overlooked potential risks, including severe complications such as infection and heavy bleeding.
In response, Danco said the ruling has created uncertainty for healthcare providers, pharmacies, and patients who rely on timely access to the medication.
GenBioPro emphasized the importance of maintaining access to safe and affordable treatment options.
Previously, the FDA had eased restrictions on mifepristone, including allowing it to be prescribed via telehealth and delivered by mail, citing evidence of its safety and effectiveness.
However, ongoing legal challenges continue to put those policies at risk.
The Supreme Court has already addressed a related case in 2024, dismissing a challenge brought by medical groups on procedural grounds.
That dispute has since been taken up by several states and remains unresolved.
Meanwhile, the debate over mifepristone continues to draw attention from lawmakers, advocacy groups, and federal officials, underscoring the broader national divide over reproductive healthcare policy in the United States.
Reuters/Hauwa M.
